Previous close | 11.95 |
Open | 12.09 |
Bid | 11.47 x 200 |
Ask | 11.53 x 800 |
Day's range | 11.44 - 12.10 |
52-week range | 8.12 - 43.69 |
Volume | |
Avg. volume | 1,026,745 |
Market cap | 412.728M |
Beta (5Y monthly) | -0.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.
Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.